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Background: Essential hypertension arises from the combined effect of genetic 
and environmental factors. A pharmacogenomics approach could help to identify 
additional molecular mechanisms involved in its pathogenesis. Aim: The aim of 
SOPHIA study was to identify genetic polymorphisms regulating blood pressure 
response to the angiotensin II receptor blocker, losartan, with a whole-genome 
approach. Materials & methods: We performed a genome-wide association study on 
blood pressure response in 372 hypertensives treated with losartan and we looked for 
replication in two independent samples. Results: We identified a peak of association 
in CAMK1D gene (rs10752271, effect size -5.5 ± 0.94 mmHg, p = 1.2 × 10-8). CAMK1D 
encodes a protein that belongs to the regulatory pathway involved in aldosterone 
synthesis. We tested the specificity of rs10752271 for losartan in hypertensives treated 
with hydrochlorothiazide and we validated it in silico in the GENRES cohort. Conclusion: 
Using a genome-wide approach, we identified the CAMK1D gene as a novel locus 
associated with blood pressure response to losartan. CAMK1D gene characterization 
may represent a useful tool to personalize the treatment of essential hypertension.
Original submitted 7 May 2014; Revision submitted 29 July 2014
Keywords:  angiotensin II receptor blockers • genome-wide association analysis • genomics  
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Background
Different classes of effective antihypertensive 
drugs that act on a variety of blood pressure 
(BP) regulating mechanisms are currently 
available. In spite of this, BP is adequately 
controlled in less than 40% of treated 
hypertensive patients. Moreover, individual 
responses to a given antihypertensive therapy 
display considerable heterogeneity [1], which 
is most likely due to diversity in the physio-
pathological and pathogenetic mechanisms 
involved in essential hypertension (EH). At 
present the choice of an antihypertensive 
drug for a patient remains empirical and can-
not be based on precise clinical, laboratory 
and instrumental a priori criteria. Although 
there have been attempts to identify which 
patients could respond to a given antihyper-
tensive drug on the basis of anthropo metric 
(e.g., age, sex and BMI) or biochemical 
(e.g., renin profile and insulin sensitivity) 
parameters, these methods have only been 
of marginal clinical use [2]. Hypertension 
arises from the combined effect of genetic 
and environmental factors, and BP variance 
explained by genetic factors is at least 30% 
[3]. Since an efficient therapy may interact 
with some of the pathways controlling BP, 
a pharmaco genomics approach using drugs 
with a known mechanism of action could 
help to detect some new steps involved in the 
pathogenesis of EH.
The aim of the SOPHIA study was to iden-
tify polymorphisms regulating BP response 
to the angiotensin II receptor blocker, losar-
tan (LOS). To address this issue we per-
formed a genome-wide association study 
(GWAS) by genotyping on the Illumina 1M 
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array [4] a sample of 494 essential hypertensive patients 
from the SOPHIA study [5] treated with LOS. We then 
verified the specificity for LOS, by testing the SNPs 
significantly associated with response to LOS in a 
sample of EH patients treated with hydrochlorothia-
zide (HCTZ). Moreover, we looked for replication of 
association of the BP response to LOS in two indepen-
dent samples of hypertensives from the GERA2 [6] and 
GENRES [7] studies.
Materials & methods
Sample description
The study was approved by the ethics committee of the 
University of Sassari (Sassari, Italy) and supported by 
the local ethics committees and all participants provided 
written informed consent to the study [5]. All study pro-
cedures were in accordance with the Declaration of 
Helsinki and the institutional/international guidelines 
on high blood pressure management: thus, our research 
was conducted according to the principles of ethics.
Supplementary Figure 1 (see online at: www.future-
medicine.com/doi/suppl/10.2217/pgs.14.119) shows 
the entire patients’ flow from the screening start 
(week -8) to the end of the study (week +4) and all 
preanalysis quality control steps. In particular, we 
enrolled 722 subjects with mild-to-moderate EH aged 
from 18 to 59 years without comorbidities. Twelve 
clinical research centers all over Italy participated in 
collecting phenotypic data and DNA samples for 
the SOPHIA study between 2005 and 2009. At the 
screening visit (week -8), patients had to display sys-
tolic BP from 140 to 179 mmHg and diastolic blood 
pressure from 90 to 109 mmHg. At each visit, office 
BP was measured in the sitting position after 5 min 
rest, three times and with a 30–60 s interval between 
readings, using a certified electronic device (OMRON 
705IT). The same range had to be confirmed 4 weeks 
later (week -4), as well as at the end of the 8 week run-
in period (week 0). To avoid or minimize carryover 
effects, 616 of the patients had never been treated for 
hypertension before, whereas the 106 who had been 
previously treated, had been in pharmacological wash-
out for at least 6 months before starting LOS. During 
a run-in period of 8 weeks, the patients followed a diet 
program that provided 100–140 mEq of sodium and 
50–70 mEq of daily potassium to minimize the life-
style differences, since sodium and potassium intake 
are known to influence intermediate phenotypes such 
as plasma renin activity and plasma aldosterone. At 
the end of this period, 50 mg/day of LOS in open 
label was prescribed orally for 4 weeks to 539 patients; 
the remaining 183 patients out of the starting cohort 
(i.e., 25.3%) had their BPs normalized during the 8 
week run-in period.
During the 4 weeks of treatment with LOS, 
21 patients left the study for poor compliance and 
24 for side effects (cough n = 15, sexual dysfunc-
tion n = 9), leaving 494 patients for genotyping and 
downstream analysis.
Additional information is available in Supple-
mentary Methods 1 and in [5].
We also compared the results of the pharmaco-
genomics of LOS to those of HCTZ in 558 EH patients 
(see Supplementary Methods 2 & Supplementary Fig-
ure 1) [8]. We tested the best findings for replication of 
association in two independent samples of hyperten-
sives of European ancestry from the GERA2 [6] and 
GENRES studies [7] (see Supplementary Methods 3). 
For all the samples, we analyzed the office BP response.
Genotyping & imputing
Genotyping details are provided in Supplemen-
tary Methods 4. DNA was extracted from periph-
eral blood with standard procedures. SOPHIA and 
HCTZ samples were genotyped using the Illumina 
Human1M-Duo array (Illumina Inc., CA, USA) 
within the HYPERGENES project [9] or the Illumina 
HumanOmniExpress array within the InterOmics 
project [10].
Genome-wide imputation was performed using 
Markov Chain based haplotyper (MACH) software 
[11] and the Caucasian (CEU) HapMap haplotypes 
(release 22), as reference. We also imputed the region 
surrounding the CAMK1D gene using MaCH with 
the 1000 Genomes haplotypes (release March 2012) as 
reference, to further enrich this locus with the highest 
number of genotypes.
Statistical analysis
The primary end point (i.e., the phenotype under 
investigation) was the change in systolic BP after 
4 weeks of treatment (ΔSBP4), which is the difference 
between systolic BP (SBP) at the end of treatment and 
SBP at the end of run-in, the day before the first pill 
of LOS.
All quality control analyses were performed in accor-
dance with the protocol proposed by Anderson et al. 
[12]. Patients’ call rate threshold was set at 0.95. For 
each patient, data from the X chromosome were used 
to check for discordance with ascertained sex. After 
imputation, SNPs with a call rate >99% and a minor 
allele frequency ≥3% were included in the analysis 
(Supplementary Methods 5 & Supplementary Figure 1).
We assessed population stratification using principal 
components analysis as implemented in EIGENSOFT 
[13,14] to infer continuous axes of genetic variation (Sup-
plementary Methods 5 & Supplementary Figure 2). To 
assess the genotype to phenotype association we per-
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formed a linear regression on ΔSBP4 under an additive 
model with adjustment for sex, age, basal SBP and for 
ancestry principal components (PCs), as implemented 
in PLINK [15].
We tested the best findings of SBP response to LOS 
(p ≤ 10-5) for association with the change in diastolic BP 
response after 4 weeks of treatment (ΔDBP4) by per-
forming a linear regression analysis under an additive 
model using sex, age, basal DBP and for the ancestry 
PCs as covariates. 
To verify that the identified markers were spe-
cific for LOS, we evaluated their predictive role on 
ΔSBP4 using an independent sample of 558 naive 
hypertensives treated with 25 mg of HCTZ for 
4 weeks as their first antihypertensive treatment 
(Supplementary Methods 2). We performed a linear 
regression analysis under an additive model using sex, 
age, basal SBP and for the ancestry PCs as covariates. 
SNP x treatment interaction analyses were conducted 
under an additive genetic model using the quantitative 
trait interaction analysis as implemented in PLINK 
[15]. Analyses on ΔSBP4 residuals were adjusted for sex, 
age, basal SBP and PCs.
To replicate our findings we tested the association in 
two independent samples of European ancestry hyper-
tensives from the GERA2 [6] and GENRES studies [7] 
(Supplementary Methods 3).
Results
Table 1 reports the characteristics of the study sample, 
composed of 372 patients.
SOPHIA participants were white Caucasians 
from continental Italy and Sardinia and included 92 
(24.7%) women. Age averaged 45.7 years (standard 
deviation [SD]: ±7.4), average basal SBP and DBP were 
148.9 mmHg (SD: ±7.1) and 96.5 mmHg (SD: ±3.7), 
respectively.
After quality control of the 494 samples genotyped, 
372 individuals and 1,705,664 SNPs were available for 
the analyses (see Supplementary Methods 5).
A quantitative trait analysis, with ΔSBP4 (adjusted 
for ancestry PCs, sex, age and basal SBP) as the 
dependent variable (Supplementary Figures 3 & 4), 
identified one SNP (rs10752271) achieving the 
genome-wide significant threshold. Moreover, the 
q–q plot showed some SNPs (p ≤ 10-5) deviat-
ing above the diagonal (the distribution reference 
line). The number of SNPs with p ≤ 10-5 was 130 
(Supplementary Table 1 & Supplementary Figure 4).
In particular, four SNPs (rs10752271, rs10906202, 
rs4747995 and rs10737061) in the CAMK1D gene 
were significantly associated with SBP response to LOS 
(Supplementary Table 1). Specifically, the imputed 
SNP rs10752271 in intron 2 reached the Bonfer-
roni’s threshold (p = 1.2 × 10-8), with an effect size 
of -5.5 ± 0.94 mmHg (G risk allele frequency = 0.10; 
Figure 1). Rs10906202 and rs4747995 (imputed and 
genotyped, respectively) in intron 3, are in linkage 
disequilibrium (LD) with rs10752271 whereas the 
genotyped rs10737061 is not in LD with rs10752271, 
although maps to approximately 600 bp upstream. All 
these SNPs showed only slightly lower p-values and 
effect sizes (Supplementary Table 1).
Owing to its highly significant association with 
ΔSBP4, we focused on CAMK1D. We fine mapped 
the gene region by imputing the 1000 Genomes haplo-
types and tested the additional genotypes for associa-
tion with LOS response. We identified another poly-
Characteristic Losartan (n = 372) HCTZ (n = 558) p-value
Men/women (n) 280/92 401/157 NS
Age (years) 45.7 ± 7.4 48.3 ± 8.8 <0.0001
BMI baseline (kg/m2) 26.9 ± 2.9 27.2 ± 3.8 NS
Pretreatment SBP (mmHg) 148.9 ± 7.1 157.1 ± 12.7 <0.0001
Pretreatment DBP (mmHg) 96.5 ± 3.7 102.3 ± 7.7 <0.0001
ΔSBP (mmHg) -11.8 ± 9.1 -14.6 ± 13.1 0.0004
ΔDBP (mmHg) -8.8 ± 6.2 -9.4 ± 8.9 NS
Serum potassium (mmol/l) 4.2 ± 0.4 4.2 ± 0.4 0.05
Urine sodium (mEq/24 h) 147.5 ± 53.9 152.8 ± 53.6 NS
Urine potassium (mEq/24 h) 62.5 ± 25.5 57.2 ± 18.4 0.0003
The table shows the characteristics of drug-treatment groups (mean ± standard deviation).
p-value of the comparison among treatment groups. Between-group comparisons of means and frequencies relied on ANOVA or χ2, as 
needed.
ΔDBP: Difference between DBP at the end of treatment and SBP at the end of run-in; ΔSBP: Difference between SBP at the end of treatment 
and SBP at the end of run-in; DBP: Diastolic blood pressure; HCTZ: Hydrochlorothiazide; NS: Not significant; SBP: Systolic blood pressure.
Table 1. Characteristics of participants by treatment.
1646 Pharmacogenomics (2014) 15(13)
Figure 1. Local Manhattan plot for the CAMK1D region. Each circle represents a SNP, the y-axis is the -log10 association p-value for 
losartan response, and the x-axis represents the physical position on the chromosome (build 37, hg19). The circles are filled with colors 
according to the linkage disequilibrium (r2) between the given SNP and the lead SNP rs1075271.
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morphism, rs10737062 not in LD with rs10752271, 
in intron 3, associated with ΔSBP4 with an effect 
size of -5.54 ± 0.96, p = 1.8 × 10-8 (G risk allele fre-
quency = 0.11, Figure 1). This SNP was not present 
in the HapMap reference panel used in the previous 
imputation.
rs10752271 was also associated with the individual 
ΔDBP4 (p = 2 × 10-5; effect size = -3.05 ± 0.71). Similar 
results were observed for the other SNPs in CAMK1D 
(Supplementary Table 2).
Among 130 SNPs with a p-value ≤10-5 in 
ΔSBP4, 121 were also associated with ΔDBP4 
(Supplementary Table 2).
To confirm the specificity of these markers for LOS, 
we tested their association with ΔSBP4 in patients 
treated with HCTZ.
Table 1 reports the characteristics of HCTZ sample. 
Within the HCTZ cohort we analyzed 558 hyper-
tensives (28.1% women). All participants were white 
Caucasians from continental Italy and Sardinia.
LOS and HCTZ samples were similar for BMI and 
urinary sodium. Urinary potassium was significantly 
higher in LOS samples compared with HCTZ; pre-
treatment BP was higher in HCTZ, whereas age was 
lower in LOS.
Among the 131 best SNPs for LOS, only ten 
were marginally associated with BP response to 
HCTZ (Supplementary Table 3). rs10752271 and 
rs10737062, did not show significant association to 
HCTZ BP response (p = 0.15, effect = -1.6 ± 1.1; 
and p = 0.48, effect = -0.8 ± 1.1, respectively; 
Figure 2 & Supplementary Table 3). We also confirmed 
the specificity of BP response to LOS by performing 
a SNP x treatment interaction analyses that was sig-
nificant for both SNPs (rs10752271, p = 0.01; and 
rs10737062, p = 0.005; Figure 2).
Replication of findings in independent samples
We tested for replication of SNP rs10752271 in two 
independent EH samples from the GERA2 [6] and 
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Figure 2. Mean systolic blood pressure response to losartan and hydrochlorothiazide relative to rs10752271 and rs10737062. 
(A) rs10752271 and (B) rs10737062. In each column, the numbers of individuals per genotype are indicated. 
†Linear regression analysis comparing genotypes in each treatment. 
‡SNP x treatment interaction analysis comparing losartan and HCTZ. 
HCTZ: Hydrochlorothiazide.
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GENRES [7] studies. GERA2 studied the effect of 
candesartan on 198 patients using a linear regression 
additive model adjusting for age and sex; GENRES 
studied the effect of LOS on 216 males using a simi-
lar linear regression model obviously omitting sex as 
covariate. In GERA2, rs10752271 was not associated 
with BP response to candesartan (p = 0.9 and effect 
size = -0.3 ± 2.55), whereas in GENRES the association 
was confirmed with a similar effect size (p = 0.04, effect 
size = -5.3 ± 2.5; Table 2 & Figure 3).
Genotypes for the imputed rs10737062 were not 
available for replication in both studies since imputation 
had been performed with HapMap as reference.
Discussion
The SOPHIA study is a genome-wide  pharmacogenomics 
assessment of the BP response to LOS.
Using a linear regression analysis, we identified 130 
SNPs associated with ΔSBP4 with p ≤ 10-5 as a depen-
dent variable. Furthermore, 121 of these 130 SNPs 
were also associated with ΔDBP4. The specificity of 
the SNPs was verified using an independent sample 
treated with HCTZ. The top hit, rs10752271 in the 
CAMK1D gene, shows an effect size of -5.5 ± 0.94 and 
a p-value of 1.2 × 10-8. This finding is supported by a 
cluster of SNPs in weak LD with each other (Figure 1).
The in silico replication in the GENRES [7] study, 
also utilizing LOS as the ARB, confirmed the associa-
tion of rs10752271 with similar effect size of the G risk 
allele (Figure 3).
The protein encodes by CAMK1D is expressed in 
the glomerular cortex where angiotensin II and potas-
sium determine increases in cytosolic calcium that 
activate CaMK1D protein. This in turn increases 
CYP11B2 gene transcription and aldosterone produc-
tion by modulating the activities of target transcription 
factors, such as NURR1, ATF1, ATF2 and CREB [16].
The importance of calcium in determining acute 
and chronic aldosterone secretion in the adrenal 
zona glomerulosa, acting largely through CaMK1D 
activation, has been consistently demonstrated [17,18]. 
CaMK1D can also regulate gene transcription by 
phosphorylating various substrates [19]. Interestingly, 
increases in intracellular calcium in the zona glomeru-
losa of the adrenal cortex, has been shown recently to 
be a common pathway in the activation of CYP11B2 
transcription in sporadic and familial hyperaldo-
steronism [20,21]. The central role of increased aldo-
sterone production in the pathogenesis of EH, has 
been un raveled in the Framingham Offspring Study, 
where aldosterone levels were directly associated with 
Studies Beta Standard error p-value
SOPHIA -5.5 0.94 1.20 × 10-8
GENRES -5.3 2.5 0.04
GERA2 -0.35 1.97 0.9
The table shows rs10752271 association results (Beta, standard 
error and p-values) for the SOPHIA, GERA2 and GENRES studies.
Table 2. In silico replication results.
1648 Pharmacogenomics (2014) 15(13)
Figure 3. Effect size of blood pressure response in SOPHIA, GENRES [7] and GERA2 [6] studies. The circles and the 
horizontal lines correspond with the effects (beta) and 95% CI of each study. 
ES: Effect size.
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an increase in blood pressure and the development of 
hypertension, independent of sodium intake and other 
potential confounding factors [22].
A major characteristic of the SOPHIA cohort is 
that it includes newly recruited never treated essen-
tial hypertensives. A complete clinical, laboratory and 
instrumental workup was made to define the diagnosis 
of ‘EH’ over a run-in period of 8 weeks with a con-
trolled diet: only those patients whose BP remained 
≥140/90 mmHg at the end of this period were included 
in the study. This should minimize the inclusion of 
‘false hypertensives’ in the study cohort. The condition 
of ‘never treated hypertensive’ was considered manda-
tory: as already well ascertained years ago [23]; up to 12 
months after treatment withdrawal may be required to 
restore BP to pretreatment levels. Moreover, the effects 
of previous drugs continue to act at the different levels 
of the biological organization thus making the findings 
of a pharmacogenomics study questionable in the case 
of a cohort composed by previously treated patients. 
We think these considerations are indeed a key point in 
the study design and conduction of a pharmacogenom-
ics study: never treated hypertensives are rather diffi-
cult to find and it took several years to assemble our 
cohort. These considerations are expressed in detail 
elsewhere [24].
To test for replication we used the GERA2 and 
GENRES studies. Different inclusion criteria were 
applied for patient’s recruitment (run-in period, basal 
BP, previous antihypertensive treatment). In spite of 
these differences we could replicate the effect size of 
our best finding in GENRES.
Previous studies used a candidate gene strat-
egy to identify SNPs that predict the BP response 
to ARBs. Conflicting results were obtained for the 
insertion/deletion polymorphism within the ACE 
gene. Some studies found the insertion allele to be 
associated with a greater decrease in BP [25], whereas 
others have not been able to confirm the finding [26,27].
Essential hypertensive patients carrying the C allele 
of the -344 T/C polymorphism in the CYP11B2 gene 
were reported to respond to ARB with a larger BP 
decrease [28], whereas this was not confirmed in the 
present study (p = 0.67).
The GENRES study evaluated the impact on 
ambulatory BP response to LOS and other antihyper-
tensive drugs of 19 loci identified in previous GWAS 
in EH. An intronic SNP in STK39 (rs6749447) was 
found to be associated with 24 h ambulatory BP 
response to LOS (p = 0.0005/0.0002 for SBP and 
DBP, respectively) [29]. We could not confirm this 
SNP (p = 0.86) and did not find additional associated 
SNPs in STK39. In a GWAS, where good respond-
ers to candesartan have been compared with poor 
responders, Turner et al. described rs11649420, in 
the gamma subunit of the SCNN1G gene, as strongly 
associated with drug response [6]. The odds of good 
BP response to candesartan, for rs11649420 GG gen-
otype, were threefold greater than for the combined 
AA+AG group, and the odds of good BP response to 
-0.35 (-5.35 to 4.65)
-5.50 (-7.34 to -3.66)
-5.30 (-10.20 to -0.40)
ES (95% CI)
rs10752271
Study
SOPHIA
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GERA2
Beta
-10 -5 0 5
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HCTZ were twofold less than the combined AA+AG 
group. We could not validate this finding either con-
trasting good and poor responders [30] or performing 
a linear regression analysis with ΔSBP as a dependent 
variable. We did not find any other associated SNP in 
SCNN1G. Recently, a GWAS on a Japanese cohort, 
performed with a design similar to that applied in the 
GENRES study, reported a marginal association with 
ABCC9 [31]. We did not replicate this finding.
Conclusion
Using a genome-wide approach, we identified in 
SOPHIA and confirmed in GENRES the CAMK1D 
gene as a novel locus associated with BP response to 
LOS (rs10752271). Because of its specific association 
with LOS, this locus could represent a novel tool for 
a genetic characterization of hypertensive patient’s 
responsiveness to an antihypertensive treatment.
Our study presents some limitations. First, we are 
aware of the limited number of SNPs at genome-wide 
association level, probably due to the small sample size 
not comparable to more powerful GWAS but in line 
with other pharmacogenomics studies. Second, we 
identified rs10752271 associated with BP response to 
LOS in two Caucasian populations; however, further 
investigation in different ethnic groups is needed.
Future perspective
There is a wide variability in antihypertensive drug 
response and data available for treatment choice are 
limited. Our study identified a novel plausible genetic 
marker associated with LOS treatment. This result 
requires further investigation to clarify the mechanism 
through which the identified gene influences LOS BP 
response.
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Executive summary
Pharmacogenomics of hypertension
•	 A pharmacogenomics approach could help to identify additional molecular mechanisms involved in the 
pathogenesis of essential hypertension.
•	 In this study a genome-wide association between polymorphisms and blood pressure response to losartan was 
evaluated in essential hypertensives.
Results: significant association between rs10752271 & blood pressure response to losartan
•	 A peak of association in the CAMK1D gene was identified. In particular rs10752271 showed an effect size of 
-5.5 ± 0.94 and a p-value of 1.2 × 10-8.
•	 We validated rs10752271 in silico in the GENRES cohort. The specificity for losartan was confirmed in a cohort 
of essential hypertensives treated with hydrochlorothiazide.
•	 CAMK1D belongs to the regulatory pathway involved in aldosterone synthesis.
Conclusion
•	 The rs10752271 polymorphism in the CAMK1D gene could represent a novel tool for individualized 
antihypertensive treatment.
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